The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! About 1.27M shares traded hands. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 54.68% since March 15, 2016 and is uptrending. It has outperformed by 49.20% the S&P500.
The move comes after 8 months positive chart setup for the $943.89M company. It was reported on Oct, 18 by Barchart.com. We have $6.84 PT which if reached, will make NASDAQ:SGYP worth $273.73M more.
Analysts await Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to report earnings on November, 14. They expect $-0.22 EPS, up 4.35% or $0.01 from last year’s $-0.23 per share. After $-0.23 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -4.35% EPS growth.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Ratings Coverage
Out of 5 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Synergy Pharmaceuticals has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was maintained by Rodman & Renshaw with “Buy” on Monday, May 9. TH Capital reinitiated the shares of SGYP in a report on Thursday, October 29 with “Buy” rating. The firm has “” rating given on Thursday, October 29 by Roth Capital. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, October 1 report. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc (NASDAQ:SGYP) rating on Monday, March 21. Rodman & Renshaw has “Buy” rating and $16 price target. BTIG Research initiated Synergy Pharmaceuticals Inc (NASDAQ:SGYP) on Tuesday, August 25 with “Buy” rating. Citigroup downgraded the stock to “Neutral” rating in Friday, December 18 report. The firm earned “Neutral” rating on Wednesday, March 16 by Citigroup.
According to Zacks Investment Research, “Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.”
Insitutional Activity: The institutional sentiment increased to 1.61 in 2016 Q2. Its up 0.55, from 1.06 in 2016Q1. The ratio is positive, as 16 funds sold all Synergy Pharmaceuticals Inc shares owned while 28 reduced positions. 25 funds bought stakes while 46 increased positions. They now own 99.69 million shares or 58.37% more from 62.94 million shares in 2016Q1.
Armistice Cap Ltd Liability Com, a New York-based fund reported 1.33 million shares. Citadel Ltd Liability has invested 0.01% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Citigroup Inc last reported 0% of its portfolio in the stock. The New Jersey-based Landscape Cap Mngmt Limited Liability Company has invested 0.24% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Hightower Advisors Llc accumulated 906,748 shares or 0.04% of the stock. The Illinois-based Css Ltd Co Il has invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Stifel Fincl reported 24,472 shares or 0% of all its holdings. Orbimed Ltd Liability Com has 0.24% invested in the company for 5.98 million shares. Blackrock Advisors Limited Company has invested 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Legal & General Grp Public Ltd Com holds 0% or 29,343 shares in its portfolio. Credit Agricole S A accumulated 4,497 shares or 0% of the stock. The Connecticut-based Great Point Prns Limited Liability Co has invested 8.26% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Morgan Stanley owns 513,424 shares or 0% of their US portfolio. Ameriprise Fincl Inc accumulated 17,390 shares or 0% of the stock. Raymond James Fin Advsrs has invested 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP).
Insider Transactions: Since September 16, 2016, the stock had 0 insider purchases, and 3 selling transactions for $19.81 million net activity. Another trade for 2,518 shares valued at $14,504 was made by BRANCACCIO JOHN P on Monday, September 19. 3.47 million shares with value of $19.49 million were sold by PAULSON & CO. INC. on Friday, September 16.
SGYP Company Profile
Synergy Pharmaceuticals Inc. (Synergy), incorporated on February 11, 1992, is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.